MedTrace Logo

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2011-09-16

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.

Conditions

Interventions

DRUG

PS433540

200mg capsule, once daily for 28 days

DRUG

placebo

placebo capsule, once daily for 28 days

DRUG

PS433540

500mg capsule, once daily for 28 days

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Joel M Neutel, MD · Integrium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-04-30
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00522925 on ClinicalTrials.gov